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Abstract
Either ribavirin (RBV) or cyclophosphamide (CY) can
shift an immune response from Th2 toward a Th1
cytokine profile. CY is used in this role in various
current cancer immunotherapy attempts but with mixed
success. More potent and reliable immunoadjuvants
and Th1 response biasing methods are needed. RBV is
used today mainly to augment interferon-alpha treat-
ment of hepatitis C. RBV shifts an immune response
from Th2 toward Th1 more effectively than CY and may
be a safe and useful adjuvant for current cancer
immunotherapeutic efforts. RBV is thought to act by
inhibition of tetrahydrobiopterin synthesis. Tetrahydro-
biopterin is an essential cofactor for all known isoforms
of nitric oxide synthase. Lowered nitric oxide favors Th1
development as high levels favor Th2 weighting.
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Introduction
This paper reviews some aspects of ribavirin (RBV) that
may be of particular interest to cancer immunologists. It
leads to several surprising conclusions. As a help to under-
standing this notion, a brief prelude reviewing the use of
cyclophosphamide (CY) to increase tissue destructive im-
mune responses will be presented. It will be shown that there
are mechanistic similarities between RBV and CY in their
shaping of immune responses.
RBV is a 244Da guanosine analogue depicted in Figure 1
that is considered a broad-spectrum anti -viral agent with
activity against both DNA and RNA viruses. RBV inhibits
inosinic acid dehydrogenase [1], and consequently can
reduce lymphocyte guanosine pools [1 ]. RBV’s oral avail-
ability is good; it is relatively well tolerated with a half - life of
298 hours. Steady state is seen clinically after several weeks
of use. The major side effect is hemolytic anemia, although
not all of those so affected need stop treatment. Induction of
mood lability and depression are occasionally a problem.
RBV doubles sustained viral clearance rates to interferon-
alpha ( IFN-alpha) treatment of chronic hepatitis C infection
(HCV) in humans.
CY, depicted in Figure 2, is a 279Da pro-drug alkylating
agent used widely in cytotoxic, cytoablative treatment
attempts for several cancers [2]. It is thought to work by
creating interstrand cross links in DNA resulting in cell death,
particularly in rapidly dividing cells. Consequently, CY is
profoundly immunosuppressive to both cell -mediated and
antibody responses [2]. Given as a single much lower dose
than that used in cytoablative cancer treatments, CY can
show an immune response enhancing effect. CY is used to
enhance the evoked immune response in several past and
current experimental cancer immunotherapy attempts.
This paper reviews data indicating that as immunization
adjuvant, both RBV and CY can under certain circumstances
and by different mechanisms, similarly shape an immune
response toward one more effective in killing malignant,
infected, or otherwise antigenetically altered host cells. The
data indicate that RBV may be safer and more potent and
reliable than CY in this regard and should be tried in
augmentation of current cancer immunotherapy attempts.
Lymphocytes, Th1 and Th2
CD4+ cells (T helper lymphocytes, Th) interact with dendritic
cells (usually monocyte lineage cells ) most commonly within
the T lymphocyte-rich areas of the lymph node. It is within the
lymph node that much of the qualitative direction or
proportion determination of Th cells takes place, to become
a Th1 or Th2 lymphocyte [3 ]. Th1 lymphocytes secrete IFN-
gamma and Il -2 among other cytokines, and Th2 lympho-
cytes secrete Il -4 and Il -10 among others and principally
augment the cell -mediated and humoral immune responses
respectively.
Cell -mediated and antibody responses can be promoted
by either Th1 or Th2 cells but cell -mediated prominent
responses are Th1 associated, Th2 are antibody prominent.
Il -2 and IFN-gamma promote strong cell -mediated, cyto-
toxic responses, and strong macrophage activation with
hundred- fold increased NO production and increased micro-
biocidal qualities particularly suited to killing of Mycobacteria
and intracellular organisms like Listeria monocytogenes
(Th1/Th2 reviewed in Ref. [3 ] ). Destruction of virus- infected
cells, or malignant cells as aimed for in cancer immunothera-
pies, has been shown to often be Th1 mediated, although not
universally so [3]. In addition, elimination of hepatitis C
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infection and destruction of pancreatic islet beta cells in type I
or insulin-dependent diabetes mellitus ( IDDM) are predom-
inantly Th1 driven. Th2-driven antigen responses tend to be
IgG1, IgE, andmast cell and eosinophil prominent responses
more suited to elimination of extracellular organisms, soluble
circulating foreign proteins, larger antigen loads such as
helminths, and other parasites. Th2 development has
elements of a default response; though it is actively
promoted by cytokines like Il -4, lower antigen-receptor
avidity, larger antigen load, and other influences [3]. Immune
responses usually involve both Th1 and Th2 responses —
the reviewed data and our discussion of CY and RBV will be
focused on response weighting to one or the other.
Cyclophosphamide
Non–obese diabetic mice (NOD) are a strain that sponta-
neously develop IDDM as early as 15 to 20 weeks of age
[4,5]. They manifest an inflammatory lymphocytic infiltrate in
the pancreas islets, insulitis, long before overt IDDM. This
prediabetic insulitis is mediated predominantly by Th2
lymphocytes [4,5 ]. At this stage, there is little or no beta
cell loss. The chronic Th2 prominent insulitis lasts months to
a year. As NOD mice age, the islet infiltrating lymphocytes
become more balanced between Th1 and Th2, and beta cell
loss rate increases [6]. At the point of massive loss of beta
cells and insulin dependence, a predominantly Th1 infiltrate
is seen [7]. Beta cells are exquisitely sensitive to destruction
by Th1 cytokines such as Il -1 beta, TNF-alpha, and IFN-
gamma [8].
A single pulse of low-dose CY will accelerate the above
transition, ending typically after 2 weeks post injection with
most mice exhibiting full IDDM [8,9]. After the CY pulse,
lymphocyte Il -12 gene activation is seen [10] and Il -12
antagonists given post-CY dampen the induced insulitis
acceleration [11]. Enhancement of cytotoxic T cell functions
after low-dose CY is partially due to CY-mediated impair-
ment of suppressor T cells [12]. CY-accelerated insulitis,
like the slower naturally occurring one, is associated with
loss of islet Th2 response, islet beta cell destruction being
Th1 mediated [7,8 ]. Th2 polarizing agents prevent or delay
CY acceleration of IDDM in NOD mice, and Th2 cytokines Il -
10 and Il -4 are protective to the islets by retarding Th2 to Th1
transition [8].
The mechanism by which CY accelerates Th2 to Th1
weighting shift in the insulitis of NOD mice is unclear but
IFN-gamma producers (Th1 lymphocytes) seem to be
relatively resistant to CY cytotoxic effects [13], conferring
selective advantage on that lymphocyte subclass. Il -4 is
important to Th2 lymphocyte development. It is produced
mainly by lymphocytes that have undergone several
divisions ( reviewed in Refs. [2,3] ). By selective killing of
actively dividing lymphocytes, the negative selection creates
a relative positive selection of Th1 cells.
Th1 weighting shift induced by CY is being used in
attempts to increase effectiveness of cancer immunothera-
pies meeting with varying success in human malignancy and
animal models. Single low-dose CY has given a weighting
shift from Il -10 (Th2) to increased Il -2 and IFN-gamma
(Th1) responses in a murine lymphoma model with resultant
decreased metastasis [14]. Such preimmunization low-
dose CY pulse has also shown benefit in experimental
murine models of melanoma [15], plasmacytoma [16], fibro-
sarcoma [17], and sarcoma [18]. Th1-mediated, macro-
phage-effected elimination of experimental murine tumors
can be seen post -CY plus Il -12 but with neither used alone
[19]. Four- fold peritumoral TNF-alpha and a Th2 to Th1
shift was documented in the fibrosarcoma model when
lipopolysaccharide was added to CY pulse [17].
In human breast and other cancers, low-dose CY has
shown some immunological and clinical benefit with
immunization with a proprietary vaccine (Theratope, an
STn-keyhole limpet hemocyanin conjugate given with a
proprietary adjuvant Detox) [20,21]. Theratope with CY
augmentation is currently in two large phase 3 trials for
breast and colon cancer. However, there have been failures
to show benefit of low-dose CY: Human trials in breast and
colon cancer of MUC-1 conjugated to mannan have shown
no clinical or immunological effects of low-dose CY [22],
nor was CY of clinical or immunological benefit in a human
melanoma vaccine trial [23]. In addition, of concern are
observations of pulse CY with methylpresnisolone being
used successfully used to induce Th1 to Th2 shift with
increased Il -4 in humans [24].
Conclusions about current clinical use of single low-
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Figure 2. Chemical structure of cyclophosphamide, 279 Da.
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situations shift an immune response from what would have
been Th2 weighted to a Th1-weighted response but there
have been clinical failures to achieve this. Th1 biasing
attribute of prevaccination CY can be used with therapeutic
cancer immunization attempts to increase tissue destructive
immune responses but constructive responses are unreliably
achieved. Under some circumstances, depending on dose,
timing with respect to antigen and others, CY can be
tolerogenic, or Th2 shifting, or generally immunosuppres-
sive, particularly if given after antigen. People with cancer
have presumably already been presented with the relevant
antigen at the time of our immunization efforts so these
threats are real. There is no immunological reason prevent-
ing concurrent Th1 biasing by CY and tolerogenizing or
immunosuppressive effects all occurring within the same
host, the net effect being whichever predominates. Even
should Th1 predominate, it would be expected to be
weakened by the tolerogenic or Th2 biasing component.
Better Th1 biasing treatments are needed.
Ribavirin
It is variously estimated that 1% to 3% of humanity is
currently chronically infected with hepatitis C virus, HCV, a
single-stranded positive sense RNA virus of the Flaviviridae
family [25]. The replication time is 24 hours and an average
total body burden is 1012 copies. About a third of those
infected eventually die of cirrhosis or hepatocellular carci-
noma because of their infection. Less than 20% of those
acutely infected clear the virus, the rest becoming chronically
infected for decades, a significant fraction of whom die of
HCV-related illnesses [25]. HCV infection is also a major
cause worldwide of disability due to chronic mild encephal-
opathy, chronic pain, fatigue, and malaise [26].
There are four immunological curiosities about HCV
infection, currently unexplained:
1. HCV is not itself hepatocellular toxic. Florid replication
can occur for years in livers of near -normal histology.
2. The observed steady-state HCV numbers over years with
a replication time of 24 hours implies viral clearance time
of 24 hours. HCV is therefore constantly being cleared
and produced. Several HCV antigens are recognized as
foreign and both antibody and cell -mediated immune
responses can be demonstrated to these antigens yet
established infection is rarely cleared without treatment.
3. HCV does not generally replicate in hepatocyte cultures in
vitro.
4. RBV as monotherapy has no measurable effect on viral
numbers in infected patients [27–31]. Liver transami-
nases are lowered during RBV monotherapy of HCV but
usually rise to pretreatment values when RBV is stopped
[29,31]. IFN-alpha monotherapy over a 1-year period
results in about 20% of patients showing sustained
clearance of HCV, though more will have temporary
reductions in viral numbers during treatment [25,32].
Addition of RBV (1000 to 1200 mg/day p.o. ) to IFN-
alpha raises sustained clearance to 40% [32].
These four curiosities would be explained if the theory that
there is some aspect of the inflammatory, immune, or other
host response to HCV or HCV- infected hepatocytes that is
required for replication were correct.
The current theory on how HCV avoids clearance by the
immune system is that its high genetic variability, with
consequent antigenic drifting results in immune system
clearance of one antigenic variant as the next comes along
[25]. That there is high genetic variability and antigenic drift
during an HCV infection seems to be proven but there is no
evidence that the immune system completely clears any
specific HCV subpopulation during a chronic infection, and
there is good evidence that the drift does not encompass T-
cell recognized epitopes [28]. No significant effect of RBV on
HCV amino acid sequence evolution was seen [28].
RBV mediates immune response weighting shift, Th2
toward Th1. How it does so is unclear. Low-dose (1 g per
Petri dish) RBV increases in vitro murine antibody response
to sheep erythrocytes [33] by suppression of T suppressor
subpopulations. In experimental immunization of mice to
hepatitis B antigens, 25 times the amounts of Th1 cytokines
Il -2 and IFN-gamma are seen in mice also receiving RBV
[27]. Also noted in that murine study was decreased IgG1
(which is enhanced by Th2 cells ) and increased IgG2
(enhanced by Th1 cells ) after RBV. Th2 to Th1 skewing was
observed in a murine hepatitis model both in vivo and in vitro
after RBV or its L enantiomer [34]. RBV and its analogues
are being explored to bias the immune system from Th2
toward Th1 in human disease treatment [34,35]. Because
nondividing lymphocytes can meet their guanosine require-
ments largely by the salvage pathway but stimulated lymp-
hocytes must meet these requirements by de novo synthesis
[36], Th2 biased lymphocytes would be selected against
during RBV treatment because they must pass through
several cell divisions and have consequent exogenous
guanosine requirements before taking on Th2 qualities [3 ].
The Nitric Oxide Connection
NO (.N— O) is a highly reactive free radical synthesized
in vessel endothelium, immune cells, brain, and other
tissues. NO is a killer. Among the many paths the immune
system uses to kill cells, NO mediated cell death figures
prominently. Although essential to host defense, at some
point of increasing NO, toxicity to host lymphocytes and the
NO synthesizing macrophages themselves becomes evident
[37]. NO is synthesized by enzymatic cleavage of the
guanido nitrogen of arginine by nitric oxide synthase, NOS,
that exists in three different isoforms; constitutive (cNOS or
NOS 3), inducible ( iNOS or NOS 2), and neural (nNOS or
NOS 1) [37]. TNF-alpha, Il -1 beta, and immune cell
activation generally give rise to increasing amounts of iNOS
mRNA followed by several hundred times the NO output of
the given cell. All three isoforms of NOS have an absolute
requirement for tetrahydrobiopterin, BH4 (Figure 3) to
function catalytically in NO synthesis [37]. BH4 is synthe-
sized in mammalian cells from guanosine 50 - triphosphate,
GTP. Since RBV lowers intracellular guanosine pools, BH4
levels drop, and with it the ability to generate NO [37,38].
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iNOS is considerably upregulated in liver mononuclear
cells during chronic infection with HCV [39–43]. This iNOS
upregulation is diffuse, seen evenly throughout the liver even
when fibrosis scores are low and antibody to HCV antigen
immunostains few isolated and scattered islands of hepato-
cytes [43]. This is prima facie evidence that HCV is doing
something to upregulate NO production beyond its immedi-
ate replicative microenvironment. Current IFN-alpha treat-
ments of HCV actually further upregulate this already
elevated intrahepatic NOS activity [44,45], thereby poten-
tially increasing, as outlined below, an NO-mediated
negative selection pressure on cytotoxic Th1 lymphocytes
that are HCV specific.
Further evidence for NO-mediated negative selection
pressure on HCV-reactive lymphocytes comes from studies
on circulating levels of lipopolysaccharide, LPS, a major
component of the cell wall of Gram-negative bacteria
(endotoxin is the historical term for LPS). LPS is one of
the most potent inducers of NO synthesis known. HCV
patients who go on to durably clear their viremia under IFN-
alpha plus RBV treatment have lower pretreatment LPS
levels than those who fail to clear [46]. In addition, 100% of
those to clear have end of treatment undetectable levels of
LPS, whereas half of those failing to clear still show
moderate LPS levels [46].
The additional 20% of complete sustained responders to
RBV-IFN over IFN monotherapy may be attributable to
RBV’s prevention of IFN-alpha-mediated increase of NO in
the milieu of cytotoxic lymphocytes. In the 20% of IFN-alpha
monotherapy patients who would have cleared if RBV had
been added, high levels of NO have caused death of
activated anti -HCV T cells. Such a mechanism was
documented by Saio et al. [47] where tumor- infiltrating
macrophages synthesized and released NO that was highly
proapoptotic to activated antitumor T lymphocytes.
A similar situation has been commonly recognized in
parasitology and mycology. High levels of NO can be
required for parasite killing but high levels of NO also can
kill responding host T lymphocytes. At some point of
increasing NO, the latter force predominates and the
parasite wins the battle. At somewhat lower doses, the par-
asite is killed, the host wins. At lower yet levels of NO, the
parasite wins again with the failure of NO-mediated parasite
killing (Ref. [48] for paracoccidioidomycosis and Ref. [49]
for echinococcosis are examples).
Analogous to these examples from parasitology, accord-
ing to the hypothesis of this paper, HCV upregulates NO
synthesis, high NO levels help HCV survive, RBV lowers NO,
permitting anti -HCV lymphocyte function to clear HCV-
infected cells.
The huge increases of NO seen during overwhelming
sepsis contribute to the observed immunosuppression of that
state [50]. The excessive NO produced by activated macro-
phages are seen to inhibit antigen-driven T lymphocyte
proliferation in diverse other situations as well [50–53]. IFN-
gamma produced by activated Th1 lymphocytes (or in
response to therapeutic use of IFN-alpha) induces several
hundred- fold increase in NO production by macrophages
[53]. High NO levels are preferentially cytotoxic to antigen-
responding Th1 lymphocytes compared to Th2 cells [52].
Thus NO, produced by macrophage lineage cells, limits
expansion of the antigen-responding T lymphocyte popula-
tion. In cancer immunotherapies and in HCV, too soon it
seems.
The above discussion of RBV and NO goes a long way
toward explaining the immunological curiosities of HCV
mentioned earlier.
Discussion
Th1-biased immune responses, often sought in current
experimental cancer immunotherapy, are thought to be more
effective in malignant cell killing than Th2-biased responses.
Low-dose CY is used for such biasing in current trials of
cancer vaccines in humans but RBV may be more effective
in this role. NO contributes to the development and evolution
of all three phases of an immune-response initiation,
maintenance, and ending. Excessive or inadequate NO
levels can impair host defenses. In pathologically high NO
states, RBV, by depriving NOS of BH4, causes NO synthetic
ability to fall. The brake on evolution of effective anti -HCV or
anti -malignant cell immune responses is thereby lessened.
The evidence from RBV use in IFN-alpha-based treatment
of HCV indicate that RBVmay bemore effective in this role in
cancer immunotherapies than is the currently used CY.
Experimental proof of this notion would be checking RBV’s
ability to accelerate IDDM in NOD mice compared to the
well -characterized actions of CY.
RBV could prove useful in other diseases where NO
overproduction is pathophysiologically important. For exam-
ple, all multiple myeloma (MM) cells investigated overex-
pressed NOS [54]. MM is a bone-eroding malignant
expansion of a post -germinal center B lymphocyte clone.
Current treatments are rarely curative but IFN-alpha can
prolong temporary remission after cytotoxic chemotherapy. If
overproduction of NO is part of MM cell’s survival strategy as
conjectured for HCV, then RBV addition should prolong yet
further IFN-alpha remissions in MM.
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